Report of the cent gardes HIV vaccine conference the B-cell response to HIV. Part 1

Broadly neutralizing antibodies fondation mérieux conference center, Veyrier du Lac, France, 5-7 November 2012

Marc P. Girard, Valentina Picot, Christophe Longuet, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). The production of cross-reactive bnAbs is one of the greatest challenges in HIV-1 vaccine development. In natural HIV infection, bnAbs are observed in only a minority of infected individuals and take a few years to develop. This report presents a comprehensive review of how these Abs arise, the possible role of viral evolution, and the activation and maturation requirements of B cell lines that lead to their production. Passive immunization with bnAbs provides efficient, cross-clade protection against simian/human immunodeficiency chimeric virus (SHIV) challenges in nonhuman primates. Despite many efforts to design immunogens that elicit them by active immunization, no immunogen other than HIV itself has yet been able to elicit a bnAb response. For this reason, innovative approaches are under investigation, including their production in the body through a gene delivery approach, vector immunoprophylaxis.

Original languageEnglish (US)
Pages (from-to)2979-2983
Number of pages5
JournalVaccine
Volume31
Issue number29
DOIs
StatePublished - Jun 24 2013
Externally publishedYes

Fingerprint

AIDS Vaccines
Neutralizing Antibodies
neutralizing antibodies
B-lymphocytes
France
B-Lymphocytes
HIV
vaccines
immunization
Human immunodeficiency virus 1
HIV-1
Cross Protection
antigens
Virus Activation
Passive Immunization
immunosuppression
vaccine development
HIV infections
Virus Diseases
gene transfer

Keywords

  • B-cell maturation
  • Broadly neutralizing antibodies
  • HIV Vaccines
  • Vectored immunoprophylaxis

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Report of the cent gardes HIV vaccine conference the B-cell response to HIV. Part 1 : Broadly neutralizing antibodies fondation mérieux conference center, Veyrier du Lac, France, 5-7 November 2012. / Girard, Marc P.; Picot, Valentina; Longuet, Christophe; Nabel, Gary J.

In: Vaccine, Vol. 31, No. 29, 24.06.2013, p. 2979-2983.

Research output: Contribution to journalArticle

@article{2cebfacb467c49698d86db48bee00032,
title = "Report of the cent gardes HIV vaccine conference the B-cell response to HIV. Part 1: Broadly neutralizing antibodies fondation m{\'e}rieux conference center, Veyrier du Lac, France, 5-7 November 2012",
abstract = "The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation M{\'e}rieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). The production of cross-reactive bnAbs is one of the greatest challenges in HIV-1 vaccine development. In natural HIV infection, bnAbs are observed in only a minority of infected individuals and take a few years to develop. This report presents a comprehensive review of how these Abs arise, the possible role of viral evolution, and the activation and maturation requirements of B cell lines that lead to their production. Passive immunization with bnAbs provides efficient, cross-clade protection against simian/human immunodeficiency chimeric virus (SHIV) challenges in nonhuman primates. Despite many efforts to design immunogens that elicit them by active immunization, no immunogen other than HIV itself has yet been able to elicit a bnAb response. For this reason, innovative approaches are under investigation, including their production in the body through a gene delivery approach, vector immunoprophylaxis.",
keywords = "B-cell maturation, Broadly neutralizing antibodies, HIV Vaccines, Vectored immunoprophylaxis",
author = "Girard, {Marc P.} and Valentina Picot and Christophe Longuet and Nabel, {Gary J.}",
year = "2013",
month = "6",
day = "24",
doi = "10.1016/j.vaccine.2013.02.068",
language = "English (US)",
volume = "31",
pages = "2979--2983",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "29",

}

TY - JOUR

T1 - Report of the cent gardes HIV vaccine conference the B-cell response to HIV. Part 1

T2 - Broadly neutralizing antibodies fondation mérieux conference center, Veyrier du Lac, France, 5-7 November 2012

AU - Girard, Marc P.

AU - Picot, Valentina

AU - Longuet, Christophe

AU - Nabel, Gary J.

PY - 2013/6/24

Y1 - 2013/6/24

N2 - The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). The production of cross-reactive bnAbs is one of the greatest challenges in HIV-1 vaccine development. In natural HIV infection, bnAbs are observed in only a minority of infected individuals and take a few years to develop. This report presents a comprehensive review of how these Abs arise, the possible role of viral evolution, and the activation and maturation requirements of B cell lines that lead to their production. Passive immunization with bnAbs provides efficient, cross-clade protection against simian/human immunodeficiency chimeric virus (SHIV) challenges in nonhuman primates. Despite many efforts to design immunogens that elicit them by active immunization, no immunogen other than HIV itself has yet been able to elicit a bnAb response. For this reason, innovative approaches are under investigation, including their production in the body through a gene delivery approach, vector immunoprophylaxis.

AB - The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). The production of cross-reactive bnAbs is one of the greatest challenges in HIV-1 vaccine development. In natural HIV infection, bnAbs are observed in only a minority of infected individuals and take a few years to develop. This report presents a comprehensive review of how these Abs arise, the possible role of viral evolution, and the activation and maturation requirements of B cell lines that lead to their production. Passive immunization with bnAbs provides efficient, cross-clade protection against simian/human immunodeficiency chimeric virus (SHIV) challenges in nonhuman primates. Despite many efforts to design immunogens that elicit them by active immunization, no immunogen other than HIV itself has yet been able to elicit a bnAb response. For this reason, innovative approaches are under investigation, including their production in the body through a gene delivery approach, vector immunoprophylaxis.

KW - B-cell maturation

KW - Broadly neutralizing antibodies

KW - HIV Vaccines

KW - Vectored immunoprophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84879013294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879013294&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.02.068

DO - 10.1016/j.vaccine.2013.02.068

M3 - Article

VL - 31

SP - 2979

EP - 2983

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 29

ER -